Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
GLP-1 agonists, through their effects on insulin secretion, glucagon suppression, and gastric emptying, are particularly effective at controlling post-meal glucose excursions
A Type II variation application has been submitted to the European Medicines Agency (EMA) seeking the approval of teclistamab (Tecvayli) monotherapy for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.1 The application is supported by data from the phase 3 MajesTEC-9 trial (NCT05572515), which showed that teclistamab reduced the risk of disease progression or death by 71% compared with standard-of-care (SOC) therapy (HR, 0.29
This question concerns patients and clinicians as semaglutide (Ozempic, Wegovy) becomes increasingly prescribed for type 2 diabetes and weight management
2 These events didnt lead to people stopping the medication, but regulators are watching it closely across the wider Phase 3 programme
US$ 25.23
US$ 27.49
US$ 21.37
US$ 27.81
US$ 26.11
US$ 28.58
US$ 28.84
US$ 23.59
US$ 24.62
